A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with BMS-936558 (Anti-PD-1) in Subjects with Advanced or Metastatic Solid Tumors
What is the purpose of this trial?
In Part 1, the primary objectives are to determine the safety and tolerability of BMS-982470 when administered weekly and 3 times weekly in combination with BMS-936558 to subjects with advanced or metastatic solid tumors and to identify a maximum tolerated dose (MTD).
In Part 2, the primary objective is to further characterize the safety and tolerability of BMS-982470 administered weekly and 3 times weekly in combination with BMS-936558 in subjects with clear cell renal cell carcinoma (ccRCC) or non-small cell lung cancer (NSCLC).
- Bristol-Myers Squibb Company
- Last Updated:
- Study HIC#: